Helicobacter pylori eradication with doxycycline-metronidazole-bismuth subcitrate triple therapy.
Triple therapy containing tetracycline HCl is currently among the most efficient combination therapies for eradication of Helicobacter pylori. Substitution of doxycycline for tetracycline HCl offers advantages of less frequent dosing and extrarenal excretion. In this study patients with duodenal ulcer or non-ulcer dyspepsia positive for H. pylori were randomized to either doxycycline or tetracycline HCl triple therapy in conjunction with bismuth subcitrate and metronidazole. Of the 34 patients taking doxycycline, only 22 (65%) achieved H. pylori eradication at the 4-week rebiopsy, compared with 36 of 39 (92%) taking tetracycline HCl (p = 0.004). We conclude that doxycycline-containing triple therapy is less effective for H. pylori eradication and offers no clinical advantage over tetracycline HCl-containing triple therapy.
Borody
T J
TJ
Centre for Digestive Diseases, Five Dock, NSW, Australia.
George
L L
LL
Brandl
S
S
Andrews
P
P
Lenne
J
J
Moore-Jones
D
D
Devine
M
M
Walton
M
M
D000328:Adult; D000368:Aged; D000863:Antacids / Q000627:therapeutic use; D001729:Bismuth / Q000627:therapeutic use; D004318:Doxycycline / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D016481:Helicobacter Infections / Q000188:drug therapy*; D016480:Helicobacter pylori / Q000302:isolation & purification*; D006801:Humans; D008297:Male; D008795:Metronidazole / Q000627:therapeutic use*; D008875:Middle Aged; D009942:Organometallic Compounds / Q000627:therapeutic use*; D013752:Tetracycline / Q000627:therapeutic use
D000863:Antacids; D009942:Organometallic Compounds; D008795:Metronidazole; D013752:Tetracycline; C002791:bismuth tripotassium dicitrate; D004318:Doxycycline; D001729:Bismuth